Key result
Elevated serum FABP4 levels after stroke are associated with 3-month mortality, suggesting FABP4 as a potential therapeutic target in cardiovascular disorders.
Answers are grounded in this paper and cite their sources.
This editorial highlights the potential of FABP4 as a novel therapeutic target in ischaemic stroke and cardiovascular diseases due to its role in linking metabolism and inflammation.
This editorial refers to ‘Adipocyte fatty acid-binding protein (A-FABP) exacerbates cerebral ischaemia injury by disrupting the blood–brain barrier’†, by B. Liao et al., on page 3169. In the last years, acute treatment options for ischaemic stroke have dramatically improved with the approval of mechanical thrombectomy and the refinements of the indications for intravenous thrombolysis.1 The armamentarium for the stroke-treating physician has also been enriched by secondary preventive strategies such as the advent of new anticoagulants and antiplatelet drug combination strategies. Moreover, an overall technology-related improvement in the area of stroke aetiological diagnosis and cardiovascular treatments has contributed to limit the risk of stroke (re-) occurrence. Nonetheless, the reduction of secondary stroke damage, and the prevention of two feared complications, blood–brain barrier (BBB) damage and haemorrhagic transformation, remain partly elusive. In this issue of the European Heart Journal,2 Liao et al. investigated the pathophysiological role of adipocyte fatty acid-binding protein (A-FABP or FABP4) in acute ischaemic stroke. FABPs are a family of highly interspecies conserved small proteins able to regulate lipid trafficking and responses in cells. Of the various isoforms expressed in different kinds of cells, FABP4 is known to be present mainly in adipocytes, but can also be up-regulated in macrophages and in endothelial cells. The interest in FABP4 relies mostly on recent evidence showing that this protein represents one key link between metabolism and inflammation in several diseases such as diabetes, obesity, acute myeloid leukaemia, cardiovascular diseases, and, in particular, atherosclerosis (Figure 1). In this latter disease, FABP4 contributes to regulating inflammasome activation in macrophages and, thus, the expression of inflammatory cytokines (interleukins IL-1β and IL-6), chemokines (monocyte chemoattractant protein-1, MCP-1), cyclooxygenase-2, and inducible nitric oxide synthase.3 , 4 The absence of FABP4 or the transplantation of FABP4-deficient bone marrow cells in experimental atherosclerosis has been shown to limit the burden of atherosclerotic plaques with an overall benefit and no observed metabolic side effects.5 , 6 In humans, an increase of serum FABP4 levels was found to occur after stroke, with an association between high levels and 3-month mortality.7 , 8 Further, individuals with an allelic variant of FABP4 causing reduced expression levels seem to have lower triglyceride levels, reduced cardiovascular risk, and reduced obesity-induced type 2 diabetes.9 Altogether, these pieces of evidence have advanced the idea that targeting such a molecule might represent a valid therapeutic approach in cardiovascular disorders.
No takes yet. Share an insight, caveat, or question.
Bacigaluppi et al. (2020) conducted an editorial in ischaemic stroke. FABP4 was evaluated. Elevated serum FABP4 levels after stroke are associated with 3-month mortality, suggesting FABP4 as a potential therapeutic target in cardiovascular disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: